A carregar...
Direct Costs Associated with Relapsed Diffuse Large B‐Cell Lymphoma Therapies
BACKGROUND. About one third of patients with diffuse large B‐cell lymphoma (DLBCL) relapse after receiving first‐line (1L) treatment of rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R‐CHOP). Relapsed patients may then be eligible for second‐line (2L) therapy. The study'...
Na minha lista:
| Publicado no: | Oncologist |
|---|---|
| Main Authors: | , , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
John Wiley & Sons, Inc.
2019
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6738309/ https://ncbi.nlm.nih.gov/pubmed/30850561 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1634/theoncologist.2018-0490 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|